Join
Live feed
·
PRReleasevia Quantisnow
HUTCHMED (China) Limited logo

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

ByQuantisnow·Wall Street's wire, on your screen.
HCM· HUTCHMED (China) Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HCM (HUTCHMED (China) Limited) and more on Quantisnow.